Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Viola Guardigni"'
Autor:
Maddalena Giglia, Giacomo Beci, Elena Rosselli Del Turco, Viola Guardigni, Alberto Amedeo, Giulia Cucchetto, Gabriella Verucchi, Marco Cipolli, Leonardo Calza, Pierluigi Viale
Publikováno v:
Monaldi Archives for Chest Disease, Vol 90, Iss 4 (2020)
We report the case of a man affected by cystic fibrosis who developed a severe SARS-CoV-2 related pneumonia in March 2020. In addition to lopinavir/ritonavir and hydroxychloroquine, he was treated with two doses of tocilizumab, displaying a significa
Externí odkaz:
https://doaj.org/article/f57e982c3a9b4e1c974cecc6a976e069
Autor:
Mario Luca Morieri, Viola Guardigni, Juana Maria Sanz, Edoardo Dalla Nora, Cecilia Soavi, Giovanni Zuliani, Laura Sighinolfi, Angelina Passaro
Publikováno v:
BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background Metabolic and cardiovascular diseases (CVD) represent a major problem in HIV infection. The aim of this study was to evaluate the relationship of HIV infection and antiretroviral therapy (ART) with circulating levels of two adipok
Externí odkaz:
https://doaj.org/article/0aaf956b69c74609b19bb04d5858bda0
Autor:
Renato Pascale, Viola Guardigni, Lorenzo Badia, Francesca Volpato, Pierluigi Viale, Gabriella Verucchi
Publikováno v:
Case Reports in Hepatology, Vol 2017 (2017)
Tenofovir disoproxil fumarate- (TDF-) related nephropathy is known to be a long-term complication of this drug, more commonly observed in HIV-infected patients, but occurring also in hepatitis B. Cases of Fanconi Syndrome associated with TDF have bee
Externí odkaz:
https://doaj.org/article/73030f76178c40c6b7c8378da5617b03
Publikováno v:
Annals of Hepatology, Vol 11, Iss 3, Pp 404-408 (2012)
Antiviral therapy in patients suffering from chronic hepatitis C virus (HCV) infection and rare comorbidities cannot be easily started, as it can reduce the likelihood of a good therapeutic response with an increased frequency of side effects. We rep
Externí odkaz:
https://doaj.org/article/0402532425de4c448c0e626e6b306660
Autor:
Alice Toschi, Eleonora Salsi, Gabriella Verucchi, Gabriele Fabbri, Laura Sighinolfi, Francesco Cristini, Viola Guardigni, Gianluca Cuomo, Lorenzo Badia, Pierluigi Viale, Marco Massari, Elena Rosselli Del Turco
Publikováno v:
AIDS. 35:1967-1972
OBJECTIVES: Hepatocellular carcinoma (HCC) has become a major issue in coinfected HIV/HCV patients with liver cirrhosis. We aimed to determine the rate of HCC occurrence after a direct-acting antiviral (DAA) treatment and to evaluate the factors asso
Autor:
Silvia Galli, Kristian Scolz, Viola Guardigni, Pierluigi Viale, Gabriella Verucchi, Elena Rosselli Del Turco, Lorenzo Badia
Publikováno v:
Hepatitis Monthly. 21
Background: A better understanding of the interaction between SARS-CoV-2 infection and HBV or HCV hepatitis is very important. Objectives: We aimed to determine the prevalence and the impact of pre-existing HBV and HCV infections in patients with COV
Autor:
Silvia Galli, Elena Rosselli Del Turco, Maria Carla Re, Pierluigi Viale, Viola Guardigni, Gabriella Verucchi, Kristian Scolz
BACKGROUND: To date, data about prevalence and clinical impact of viral hepatitis in COVID-19 are scarce and conflicting.METHODS: We conducted an observational, retrospective study including all subjects tested positive for SARS-CoV-2 from March to M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9878d0fbe79692e9108eb66303cab6f7
https://doi.org/10.21203/rs.3.rs-99544/v1
https://doi.org/10.21203/rs.3.rs-99544/v1
Autor:
Leonardo Calza, Marco Cipolli, Maddalena Giglia, Gabriella Verucchi, Giacomo Beci, Viola Guardigni, Giulia Cucchetto, Pierluigi Viale, Elena Rosselli Del Turco, Alberto Amedeo
Publikováno v:
Monaldi Archives for Chest Disease, Vol 90, Iss 4 (2020)
We report the case of a man affected by cystic fibrosis who developed a severe SARS-CoV-2 related pneumonia in March 2020. In addition to lopinavir/ritonavir and hydroxychloroquine, he was treated with two doses of tocilizumab, displaying a significa
Autor:
Ciro Fulgaro, Ioannis Tzimas, Luigi Raumer, Marianna Meschiari, Marianna Menozzi, Gabriella Verucchi, Giada Rossini, Filippo Trapani, Giacomo Fornaro, Michela Semprini, Alessandra Cascavilla, Emanuele Campaci, Maddalena Giannella, Luigia Scudeller, Alessandro Zuccotti, Irid Baxhaku, Lucia Angelelli, Eleonora Zamparini, Annalisa Saracino, Alberto Zuppiroli, Cristina Basso, Elisabetta Pierucci, Agostino Rossi, Giulia Santangelo, Paolo Gaibani, Francesco Cristini, Francesca Volpato, Elisa Fronti, Giovanni Guaraldi, Alberto Sarti, Giorgio Legnani, Mattia Neri, Mauro Codeluppi, Adriana Badeanu, Giulio Virgili, Chiara Pironi, Lorenzo Marconi, Sara K. Tedeschi, Vidak Koprivika, Francesco Barchiesi, Luciano Attard, Matteo Rinaldi, Paola Laghetti, Stefano Antonini, Linda Bussini, Caterina Campoli, Giacomo Urbinati, Marco Merli, Nicholas Roncagli, Agnese Pratelli, Elena Rosselli Del Turco, Silvia Rapuano, Luca Guerra, Stefano Ianniruberto, Francesco Dell'Omo, Michele Bartoletti, Livia Pancaldi, Viola Guardigni, Fabio Tumietto, Giuseppe Sasdelli, Vito Marco Ranieri, Flovia Dauti, Giovanni Fasulo, Eugenia Francalanci, Nicola Dentale, Amalia Sanna Passino, Tommaso Zanaboni, Arianna Rubin, Davide Fiore Bavaro, Idina Zavatta, Massimo Puoti, Letizia Pasinelli, Maria Cristina Leoni, Pierluigi Viale, Oana Vatamanu, Elena Piccini, Renato Pascale, Cristina Mussini, Luca Esposito, Simona Coladonato, Alice Gori, Giulia Tesini, Lorenzo Badia, Mara D'Onofrio, Alberto Licci, Enrico Evangelisti, Guido Maria Liuzzi, Giacinto Pizzilli, Nicolò Rossi, Tommaso Tonetti, Marina Tadolini, Zeno Pasquini, Caterina Vocale
Publikováno v:
Clinical Microbiology and Infection
Objectives: We aimed to develop and validate a risk score to predict severe respiratory failure (SRF) among patients hospitalized with coronavirus disease-2019 (COVID-19). Methods: We performed a multicentre cohort study among hospitalized (>24 hours
Autor:
Gabriella Verucchi, Silvia Galli, Isabella Bon, Viola Guardigni, Lorenzo Badia, Bianca Granozzi
No data on the risk of HBV reactivation in HCV-HIV co-infected patients undergoing DAAs have been published yet. According to international guidelines , all HIV-infected and HBsAg-positive patients should be treated with antiretroviral therapy (ART)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::562e63635f4e2828f011f5aa1b123e91
http://hdl.handle.net/11585/800612
http://hdl.handle.net/11585/800612